Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease

• DOI: 10.2146/ajhp110149
• Publication Date: 2012-01-04T00:36:11Z
• Authors: Amy K. O’Sullivan; Milton C. Weinstein; Ankur Pandya; David Thompson; Amelia A. Langston; John R. Perfect; George Papadopoulos
• Keywords: Posaconazole; Incremental cost-effectiveness ratio

The results of a pharmacoeconomic study the cost-effectiveness posaconazole versus fluconazole in preventing invasive fungal infections (IFIs) patients with graft-versus-host disease (GVHD) are reported.The randomized clinical trial suggested that may be as effective for prevention IFIs recipients allogeneic cell transplants who develop severe GVHD and superior to reducing IFI-related deaths. Using published data from secondary sources, an economic model was developed estimate costs, avoided, life-years saved therapy. modeled 112-day treatment simulation were extrapolated lifetime horizon.In simulation, therapy associated lower probability IFI development (0.05 0.09), increased discounted (7.87 7.66 life-years), higher costs per patient ($8,860 $5,710 2006 U.S. dollars) relative estimated incremental prophylaxis $85,300 avoided $15,300 life-year saved. A sensitivity analysis indicated 90% use this purpose would cost-effective at threshold $50,000 saved.Posaconazole is range currently accepted criteria cost- effectiveness among GVHD.